AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 335498 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-200 mg spironolactone
Number of subjects: 40
Study 335498 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone
Number of subjects: 40
Study 335498 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone with other antihypertensive regimens
Number of subjects: 40
Study 29427176 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous golimumab 50 mg every 4 weeks (q4w) through week 12, continued for responders through week 52.
Number of subjects: 433
Study 29427176 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous golimumab 50 mg q4w through week 44 (N = 75).
Number of subjects: 433
Study 29427176 — intervention group
Group type: COMPARATOR
Intervention: Double-blind subcutaneous golimumab 50 mg q4w or intravenous golimumab 2 mg/kg (weeks 16, 20, every 8 weeks [q8w]) for nonresponders.
Number of subjects: 433
Study 29427176 — intervention group
Group type: COMPARATOR
Intervention: Previous adalimumab/etanercept treatment.
Number of subjects: 433
Study 26712088 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-Fix
Number of subjects: 165
Study 26712088 — intervention group
Group type: EXPERIMENTAL
Intervention: LockIt Plus
Number of subjects: 165
Study 26712088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 165
Study 25180016 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) therapy
Number of subjects: 60
Study 25180016 — intervention group
Group type: EXPERIMENTAL
Intervention: Best conventional medical practice with SCS
Number of subjects: 60
Study 25180016 — intervention group
Group type: COMPARATOR
Intervention: Best conventional medical practice without SCS (control group)
Number of subjects: 60
Study 22721736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatching redundant amodal information (viewed cylinders while holding a rectangular cube)
Number of subjects: 0
Study 22721736 — intervention group
Group type: COMPARATOR
Intervention: Matching redundant amodal information (not explicitly mentioned but implied)
Number of subjects: 0
Study 21072973 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment FP (fentanyl 0.02 mg kg(‐1) and propofol 12.0 mg kg(‐1) hour(‐1))
Number of subjects: 6
Study 21072973 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment MP (midazolam 0.3 mg kg(‐1) and propofol 12.0 mg kg(‐1) hour(‐1))
Number of subjects: 6
Study 18682011 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual behavioural counselling using motivational interviewing techniques
Number of subjects: 141
Study 18682011 — intervention group
Group type: COMPARATOR
Intervention: Information leaflets
Number of subjects: 141
Study 16191135 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for physicians
Number of subjects: 30
Study 16191135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 30
Study 12712062 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam syrup
Number of subjects: 0
Study 12712062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 5 mg
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 7.5 mg
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 10 mg
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 643
Study 10972633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan (any dose)
Number of subjects: 643
Study 10972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (any dose)
Number of subjects: 643
Study 8761583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (S-P) given as a single dose of 0.8-1.4 mg pyrimethamine/kg body weight
Number of subjects: 38
Study 8761583 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 38
Study 8761583 — intervention group
Group type: COMPARATOR
Intervention: Weekly dapsone-pyrimethamine prophylactic intervention
Number of subjects: 38
Study 1423200 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent 5‐fluorouracil, cisplatin, and radiation therapy
Number of subjects: 42
Study 2862111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine + Cimetidine
Number of subjects: 8
Study 2862111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine + Ranitidine
Number of subjects: 8
Study 2862111 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine
Number of subjects: 8
Study 2862111 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 8
Study 31679951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving Through Dance intervention using Google Glass for three weeks
Number of subjects: 7
Study 29442143 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 32
Study 29442143 — intervention group
Group type: COMPARATOR
Intervention: Fixation strips
Number of subjects: 32
Study 28476710 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive interventional therapy
Number of subjects: 128
Study 28476710 — intervention group
Group type: COMPARATOR
Intervention: Drug conservative therapy
Number of subjects: 128
Study 24920862 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of interictal epileptiform discharges (IEDs)
Number of subjects: 23
Study 24920862 — intervention group
Group type: COMPARATOR
Intervention: No IEDs
Number of subjects: 23
Study 22480442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone microspheres
Number of subjects: 62
Study 22480442 — intervention group
Group type: COMPARATOR
Intervention: Long-acting injectable haloperidol or fluphenazine (stayers)
Number of subjects: 62
Study 20417052 — intervention group
Group type: COMPARATOR
Intervention: SES (Sirolimus-Eluting Stent)
Number of subjects: 1007
Study 20417052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-DES (Dual Drug-Eluting Stent)
Number of subjects: 1007
Study 20417052 — intervention group
Group type: COMPARATOR
Intervention: ZES (Zotarolimus-Eluting Stent)
Number of subjects: 1007
Study 17907073 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine analgesia
Number of subjects: 898
Study 17907073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898
Study 17907073 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional analgesia (AA)
Number of subjects: 898
Study 15633203 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/day) for 8 weeks
Number of subjects: 64
Study 15633203 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 8 weeks
Number of subjects: 64
Study 15633203 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/day) for 8 weeks (crossover group)
Number of subjects: 64
Study 11890432 — intervention group
Group type: EXPERIMENTAL
Intervention: HT only (standard HT care)
Number of subjects: 22
Study 11890432 — intervention group
Group type: EXPERIMENTAL
Intervention: HT+ (Standard HT care plus music plus guided imagery)
Number of subjects: 22
Study 11890432 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 22
Study 10480511 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged women
Number of subjects: 174
Study 10480511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both young and middle-aged women
Number of subjects: 174
Study 9089530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-Service (FFS) option
Number of subjects: 3655
Study 9089530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based Fee-for-Service (FFS) dental patients
Number of subjects: 3655
Study 9089530 — intervention group
Group type: COMPARATOR
Intervention: Hospital HMO
Number of subjects: 3655
Study 1993791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior left ventricular patch as an anode
Number of subjects: 40
Study 1993791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior left ventricular patch as a cathode
Number of subjects: 40
Study 6389814 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instructions for mixing the solution along with a pre‐marked container (group I)
Number of subjects: 86
Study 6389814 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instructions only (group II)
Number of subjects: 86
Study 6389814 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarked container only (group III)
Number of subjects: 86
Study 6389814 — intervention group
Group type: COMPARATOR
Intervention: Neither written instructions nor premarked container (group IV)
Number of subjects: 86
Study 29779435 — intervention group
Group type: EXPERIMENTAL
Intervention: Content acquisition and reading comprehension intervention (comprehension canopy, essential words, knowledge acquisition, team-based learning)
Number of subjects: 690
Study 29779435 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (standard instructional practices)
Number of subjects: 690
Study 30308388 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d; 3/1 schedule) plus fulvestrant (500 mg)
Number of subjects: 521
Study 30308388 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg)
Number of subjects: 521
Study 26853648 — intervention group
Group type: EXPERIMENTAL
Intervention: CMVPepVax vaccine
Number of subjects: 36
Study 26853648 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 36
Study 24072758 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol assessment and feedback (group 1)
Number of subjects: 7809
Study 24072758 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol assessment only without feedback (group 2)
Number of subjects: 7809
Study 24072758 — intervention group
Group type: COMPARATOR
Intervention: No contact, neither assessment nor feedback (group 3)
Number of subjects: 7809
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 0.5 mg every 4 weeks
Number of subjects: 159
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 2 mg every 4 weeks
Number of subjects: 159
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 0.5 mg every 12 weeks
Number of subjects: 159
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 2 mg every 12 weeks
Number of subjects: 159
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 4 mg every 12 weeks
Number of subjects: 159
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye (all groups combined)
Number of subjects: 159
Study 21640257 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye (2 mg q4wk and 2 mg q12wk)
Number of subjects: 159
Study 19459420 — intervention group
Group type: EXPERIMENTAL
Intervention: One combined inhaled drug containing glucocorticosteroids (GCS) and long‐acting beta2‐agonists (LABA)
Number of subjects: 47
Study 16850291 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous disc chondrocyte transplantation (ADCT) plus discectomy
Number of subjects: 0
Study 16850291 — intervention group
Group type: COMPARATOR
Intervention: Discectomy alone (Control)
Number of subjects: 0
Study 15296796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (700 IU/day for 1 month)
Number of subjects: 20
Study 15296796 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 11782045 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0
Study 11782045 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study 9028818 — intervention group
Group type: EXPERIMENTAL
Intervention: QSC + SBF
Number of subjects: 427
Study 9028818 — intervention group
Group type: EXPERIMENTAL
Intervention: QSC + EBF
Number of subjects: 427
Study 9028818 — intervention group
Group type: EXPERIMENTAL
Intervention: QSC
Number of subjects: 427
Study 8101126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam and exposure (combined treatment)
Number of subjects: 154
Study 8101126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam and relaxation (psychological placebo)
Number of subjects: 154
Study 8101126 — intervention group
Group type: COMPARATOR
Intervention: Placebo and exposure
Number of subjects: 154
Study 8101126 — intervention group
Group type: COMPARATOR
Intervention: Placebo and relaxation (double placebo)
Number of subjects: 154
Study 3434999 — intervention group
Group type: EXPERIMENTAL
Intervention: Home preparation with 3 liters balanced electrolyte solution (BES)
Number of subjects: 62
Study 3434999 — intervention group
Group type: COMPARATOR
Intervention: Hospital preparation with 3 liters balanced electrolyte solution (BES)
Number of subjects: 62
Study 3434999 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients unable to drink 3 liters of BES within 2 hours
Number of subjects: 62
Study 29527927 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) administration
Number of subjects: 12
Study 29527927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 27176869 — intervention group
Group type: EXPERIMENTAL
Intervention: LGP‐HAL (Restylane Lyft; Galderma Laboratories, L.P.)
Number of subjects: 0
Study 27176869 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 27176869 — intervention group
Group type: EXPERIMENTAL
Intervention: LGP‐HAL
Number of subjects: 0
Study 24407028 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (R)
Number of subjects: 17
Study 24407028 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 17
Study 22018755 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Number of subjects: 20
Study 22018755 — intervention group
Group type: COMPARATOR
Intervention: Control (special attention)
Number of subjects: 20
Study 20728636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (BAC=0.05%)
Number of subjects: 12
Study 20728636 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (13 mg)
Number of subjects: 12
Study 20728636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alcohol and THC
Number of subjects: 12
Study 20728636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (drinking and smoking)
Number of subjects: 12
Study 19001103 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CME seminar about type 2 diabetes
Number of subjects: 113
Study 19001103 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CME seminar about systolic heart failure
Number of subjects: 113
Study 19001103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 113
Study 19479627 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 37
Study 19479627 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-plyometric training (P)
Number of subjects: 37
Study 19479627 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-VertiMax without arms (VNA)
Number of subjects: 37
Study 19479627 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-VertiMax with arms (VA)
Number of subjects: 37
Study 19479627 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 37
Study 16113584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical management
Number of subjects: 90
Study 16113584 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 90
Study 16113584 — intervention group
Group type: EXPERIMENTAL
Intervention: E3/4 genotype
Number of subjects: 90
Study 12195058 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 260
Study 12195058 — intervention group
Group type: COMPARATOR
Intervention: Intensive dynamic strengthening training
Number of subjects: 260
Study 9782692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 231
Study 9782692 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacy care
Number of subjects: 231
Study 8151912 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 capsules (375 mg, twice a day for 7 days)
Number of subjects: 199
Study 8151912 — intervention group
Group type: COMPARATOR
Intervention: S6472 granules (375 mg, twice a day for 7 days)
Number of subjects: 199
Study 8151912 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 capsules
Number of subjects: 199
Study 8151912 — intervention group
Group type: COMPARATOR
Intervention: S6472 granules
Number of subjects: 199
Study 8151912 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 capsules and granules
Number of subjects: 199
Study 3280080 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 750 mg daily
Number of subjects: 40
Study 3280080 — intervention group
Group type: COMPARATOR
Intervention: Stilboestrol 3 mg daily
Number of subjects: 40
Study 11266233 — intervention group
Group type: EXPERIMENTAL
Intervention: Active reflexology
Number of subjects: 40
Study 11266233 — intervention group
Group type: COMPARATOR
Intervention: Simulated (placebo) reflexology
Number of subjects: 40
Study 31597552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 1349
Study 31597552 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus migration
Number of subjects: 1349
Study 31597552 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus migration in M1 initial target occlusion
Number of subjects: 1349
Study 31597552 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus resolution
Number of subjects: 1349
Study 30008335 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pedometer assisted physical activity (Group 1)
Number of subjects: 40
Study 30008335 — intervention group
Group type: COMPARATOR
Intervention: Outpatient supervised exercise training program (Group 2)
Number of subjects: 40
Study 26538427 — intervention group
Group type: EXPERIMENTAL
Intervention: IT + HBO treatment
Number of subjects: 80
Study 26538427 — intervention group
Group type: COMPARATOR
Intervention: IV + HBO therapy
Number of subjects: 80
Study 25376735 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) at a high dose of 100,000 UI every 2 weeks for 2 months then monthly for 22 months
Number of subjects: 640
Study 25376735 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (cholecalciferol) at a low dose of 12,000 UI every 2 weeks for 2 months then monthly for 22 months
Number of subjects: 640
Study 25376735 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (100,000 IU)
Number of subjects: 640
Study 25376735 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cholecalciferol (12,000 IU)
Number of subjects: 640
Study 22611047 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1846
Study 22611047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1846
Study 20545873 — intervention group
Group type: EXPERIMENTAL
Intervention: Website (painACTION-Back Pain)
Number of subjects: 209
Study 20545873 — intervention group
Group type: COMPARATOR
Intervention: Control (text-based material)
Number of subjects: 209
Study 17916259 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PSA decision-aid, Prosdex
Number of subjects: 0
Study 17916259 — intervention group
Group type: COMPARATOR
Intervention: Control group (paper version of Prosdex)
Number of subjects: 0
Study 17916259 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 0
Study 17916259 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 15704028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 36
Study 12005464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transpyloric feeding during tracheal extubation
Number of subjects: 59
Study 12005464 — intervention group
Group type: COMPARATOR
Intervention: Interrupted transpyloric feeding (discontinued 4 hours before extubation and restarted 4 hours after)
Number of subjects: 59
Study 10407712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg BID
Number of subjects: 481
Study 10407712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.5 mg BID
Number of subjects: 481
Study 10407712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 1 mg QD
Number of subjects: 481
Study 10407712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg QD
Number of subjects: 481
Study 10407712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 7539817 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH; 0.025 mg/kg.day)
Number of subjects: 16
Study 7539817 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose recombinant human insulin-like growth factor-I (rhIGF-I; 0.015 mg/kg, twice daily)
Number of subjects: 16
Study 7539817 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose recombinant human insulin-like growth factor-I (rhIGF-I; 0.060 mg/kg, twice daily)
Number of subjects: 16
Study 2161626 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg 3 times a day)
Number of subjects: 10
Study 2161626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 81412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertransfusion to a haemoglobin of 16‐‐18 g/dl (group B)
Number of subjects: 26
Study 81412 — intervention group
Group type: COMPARATOR
Intervention: Transfusion to a haemoglobin of 10‐‐12 g/dl (group A)
Number of subjects: 26
Study 30887178 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib + gemcitabine
Number of subjects: 156
Study 30887178 — intervention group
Group type: COMPARATOR
Intervention: Placebo + gemcitabine
Number of subjects: 156
Study 29206629 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg
Number of subjects: 184
Study 29206629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184